Still sick on a strict gluten-free diet? How antigliadin testing reveals cross-contamination

Understanding Anti-Gliadin on the GI-MAP: What It Can (and Can’t) Tell You

When reviewing a GI-MAP stool test, one marker that often stands out is anti-gliadin IgA. This marker is commonly interpreted as a sign of how your gut immune system is reacting to gluten, specifically to gliadin, a protein found in wheat.

It’s important to clarify upfront: this is not a diagnostic test for celiac disease. Instead, it is intended to reflect localized immune activity in the gut.

Anti-gliadin antibodies are part of the immune system’s response to gluten exposure. Historically, these antibodies were used in blood testing for celiac disease, but they have largely been replaced by more accurate markers such as tissue transglutaminase (tTG) antibodies due to better sensitivity and specificity . That shift highlights an important point: not all anti-gliadin testing carries the same diagnostic weight.

On a stool test like the GI-MAP, anti-gliadin IgA reflects secretory IgA activity in the gut lining. In theory, an elevated level suggests that the immune system in the gastrointestinal tract is recognizing gliadin as a threat and mounting a response.

This can be clinically useful in a few contexts.

First, for individuals who are actively consuming gluten and experiencing symptoms, an elevated anti-gliadin IgA may indicate that the immune system is reacting to gluten at the mucosal level. While this does not confirm celiac disease or even non-celiac gluten sensitivity, it can provide a clue that gluten may be contributing to symptoms.

There is some evidence that individuals without celiac disease can still exhibit immune activation in response to wheat. Research has shown that people with non-celiac wheat sensitivity may demonstrate systemic immune activation and intestinal barrier dysfunction when exposed to wheat-related components . This supports the idea that immune responses to gluten can exist outside of classic celiac disease.

Second, this marker is sometimes used in individuals who report being strictly gluten-free but continue to experience symptoms. In these cases, a positive anti-gliadin IgA is often interpreted as a possible sign of ongoing exposure, such as cross-contamination.

However, this is where interpretation becomes more nuanced.

Studies evaluating stool-based anti-gliadin antibodies have shown significant limitations. For example, research assessing fecal anti-gliadin IgA found very low sensitivity for detecting celiac disease, meaning the test often fails to identify true cases . Because of this, stool antibody testing is not considered reliable for diagnosing or screening for celiac disease in conventional medicine.

Additionally, there are currently no validated biomarkers for non-celiac gluten sensitivity, and diagnosis is still based primarily on symptom response to dietary elimination and reintroduction.

So where does that leave anti-gliadin on the GI-MAP?

It can be viewed as a marker of immune activity in the gut that may be associated with gluten exposure. It may provide context when interpreted alongside symptoms, diet history, and other clinical findings. But it should not be used in isolation to diagnose gluten-related disorders or to definitively confirm cross-contamination.

A practical approach is to use this marker as a piece of a larger puzzle. If it is elevated, it may warrant a closer look at gluten intake, food preparation practices, and symptom patterns. If gluten-related disorders are suspected, more established testing, such as serum tTG antibodies and appropriate medical evaluation, should be considered.